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1. Introduction
  Cellular immunotherapy is a new treatment for leukemia 
following chemotherapy and hematopoietic stem cell 
transplantation, which is mainly because many tumor 
cells are resistant to immunologic effector cells. Leukemia 
patients themselves with immune dysfunction and antigen 
presentation dysfunction, further increase the tumor cells 
escape immune response[1]. Cytokine-induced killer (CIK) 
cells have the characteristics of broad spectrum in killing of 
tumor cells[2] and equally sensitive to multi-drug resistant 
tumor cells. Dendritic cells (DC) is an efficient antigen-
presenting cells which can be united applicated with CIK 
and increase the specificity of the response of CIK cells[3]. 
Therefore, in order to effectively remove residual leukemia 
cells and reduce the relapse rate in patients with leukemia, 
this paper observed the impact of DC combined CIK on the 
killing effect of leukemia HL-60 DC cell.
2. Materials and methods
2.1. Materials
  Human leukemia HL-60 was purchased from cell bank of 
Institute of Shanghai Institutes for Biological Sciences, CAS., 
lymphocyte separation medium was purchased from Tianjin 
TBD, 1640 were purchased from Sigma Chemical Co.,  MTT 
and formazan were purchased from Gibco. ELISA kits of 
IFN-毭, IL-8 and TNF-毩 were purchased from Jingmei 
Biological Engineering Co., Ltd.. Cord blood was provided 
by obstetrics and gynecology of Xx Hospital (obtained from 
infants delivered by full term healthy woman under sterile 
Objective: To observe the effect of co-culture cytokine-induced killer cells (CIK) and 
homologous dendritic cells (DC) on the proliferative activity and phenotype change of the DC-
CIK cell and the cell killing activity of leukemia HL-60. Methods: 50 mL cord blood sample 
was obtained from infants delivered by full term healthy woman and the cord blood mononuclear 
cells were isolated by density gradient centrifugation. Non-adherent cells were collectedfor the 
induction culture of CIK, adherent cells were differentiated into mature DC; cultured mature DC 
was mixed with and CIK in the proportion of 1:5 for 12 d. Killing activity of DC-CIK co-cultured 
cell on leukemia HL-60 was detected by MTT assay. Results: Compared with CIKs, the co-
cultured DC-CIKs presented a markedly higher proliferation and killing activity. Conclusions: 
Co-culture of DC-CIK cells led to a significant increase of the proliferation and cytotoxicity of 
CIK.
Hui-Qing Qu et al./Asian Pacific Journal of Tropical Medicine (2014)659-662660
conditions and anticoagulated with Sodium heparin).
2.2 .CIK and DC induction, amplification and culture
2.2.1. Culture of DC
  Cord blood was obtained from infants delivered by full term 
healthy woman and anticoagulated with Sodium heparin. 
Mononuclear cells (MNC) were isolated with lymphocyte 
separating medium and washed by serum-free RPMI 1640 
culture medium. They were cultured in RPMI 1640 medium 
for 2 h. Adherent cells were suspended in RPMI 1640 culture 
medium which contained rhGM-CSF 550 U/mL, rhIL 4 500 U/mL,
rhSCF 100 毺g/L, rhTNF 毩 10 毺g/L for 10 d. Medium 
was changed every other day for half dose and added with 
cytokines.
2.2.2. Culture of CIK
  Non-adherent cells of cord blood MNC were collected, 
washed with serum-free RPMI 1640 culture medium and 
the MNC cell concentration was adjusted to 1×106/m. 
Interferon-毩 (IFN-毩) 1 000 U/mL was addedand and they 
were cultured in the CO2 incubator at constant temperature 
37 曟. After 24 h, 1 g/mL CD3 monoclonal antibody, 1 000 U/mL
recombinant human interleukin-2 (rh IL-2) and 300 U/mL 
recombinant human interleukin-1 (rh IL-1) were added. 
Medium was changed every three days for half dose and 
added with cytokines to maintain the cell concentration at 
(1-2)×106/mL.
2.2.3. DC co-cultured with CIK
  Mature DC was obtained and CIK and they were cultured 
in the proportion of 1:5 after the cells were counted. Medium 
containing 500 U/mL rh IL-2.Cells were collected for 
biological activities assay after 12 d.
2.3. MTT assay detect the killing activity of DC-CIK cell on 
target cells
  HL-60 cells were used as target cells, the CIK and DC-CIK 
cells cultured for 12 d were used as effector cell mixed in 
the proportion 5:1, 10:1 and 20:1. Leukemia HL-60 cells was 
obtained at logarithmic growth phase and concentration was 
adjusted to 1×105/mL, then the CIK and DC-CIK cells were 
adjusted according to effector-target ratio, respectively. 
They were divided into three groups, the experimental 
group, the effector cell group and the target cells group. 
There were 3 parallel holes at every group. Experimental 
group were added with effector cells and target cells 100 毺L
respectively. Effector cell group were added with effector 
cells and 1640 culture medium 100 毺L respectively. 
The target cell groups were added target cells and 1640 
culture medium 100 毺L respectively and all cells were 
cultured in the CO2 incubator at constant temperature 37 曟.
MTT reagent 10 毺L was added after 48 h, formazan solution 
100 毺L was added after 4 h. Absorbance was measured at 
wave length of 570 nm with automated immunoanalyser after 
4 h, killing rate was calculated as follows: The killing rate 
(%) = [1 - (A effect target cell well-A effector cell well)/A 
target cell well] 暳100%.
2.4. Immune phenotype and cytokine expression were detected
  Cultured cells were collected and the immune phenotype 
of DC cells, CIK cells, DC-CIK cells were detected with flow 
cytometry. IFN-毭, IL-8 and TNF-毩content of the cell 
supernatants were measured with ELISA.
2.5. Statistical analysis
  The data were analyzed by SPSS 17.0 statistics software and 
the measurement data were expressed as mean依SD values. 
t-test was used to evaluate the differences between groups. 
P<0.05 was considered as statistical significant difference.
3. Results
3.1. Cell proliferation
  Cord blood CIK cells proliferation began  at the first three 
days after culturing. Cells were colony-like suspended 
growth under invert microscope. Part of the cell became 
larger and irregular shape. Cells were quickly proliferated 
from the 5-6 d, most of the cells became larger (Table 1).
Table 1
Comparison of CIK and DC-CIK proliferation multiple at different 
times.
Groups  3 Days 6 Days 9 Days 12 Days
CIK group 1.9依0.5 5.3依1.5 9.2依2.6 14.3依2.6
DC-CIK group 1.9依0.4 5.3依1.4 9.3依2.8   20.5依3.2*
Note: Compared with CIK group, *P<0.05.
3.2. Analysis of cell phenotype
  Flow cytometry showed that with the culture time, CD3+ 
CD8
+ cell percentage gradually increased. After co-cultured 
with DC, CD3+ CD8+ cell percentage was increased more 
significantly than the simple CIK (P<0.05) (Table 2).
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Table 2
Cord blood CIK and DC-CIK cells phenotype at different times.
Groups  3 d 6 d 9 d 12 d
CIK group 1.8依0.5 5.2依1.3 9.2依2.1 15.5依2.6
DC-CIK group 1.8依0.4 5.3依1.2 9.3依2.3   21.3依3.0*
Note: Compared with CIK group, *P<0.05.
3.3. Measured the secretions of cytokines of DC-CIK and CIK 
cells
  At 12 d of culturing cord blood CIK and DC cells, it was 
found that the IFN-C, TNF-毩 and IL-8 levels of DC-CIK 
cells were significantly greater than the simple CIK cells 
(P<0.05) (Table 3).
Table 3
Comparison of cord blood CIK and DC-CIK cells cytokine secretion.
Groups IFN-毭 TNF-毩 IL-8
CIK group 85.2依28.3 76.3依25.9 55.7依17.8
DC-CIK group 227.6依81.9* 137.5依40.2*   78.5依21.5*
Note: Compared with CIK group, *P<0.05.
3.4. DC-CIK and CIK killing activity
  HL-60 leukemia cells were used as target cells. CIK and 
DC-CIK cells both had a strong killing effect on HL-60, and 
the killing effect became more significant with the increase 
of effector-target ratio (P<0.05). Under the same effector-
target ratio, the killing effect of DC-CIK cells on HL-60 cells 
was more significant than the CIK cells (P<0.05) (Table 4).
Table 4
Comparison of CIK and DC-CIK killing activity under different 
effector-target ratio.
Effector-target ratio CIK group DC-CIK group
  5:1 20.2依2.1 30.8依2.6*
10:1   36.7依2.9△   45.6依3.3*△
20:1   52.9依3.8○   62.8依4.5*○
Note: Compared with the same effector-target ratio, *P<0.05; 
compared with the 5:1 effector-target ratio,△P<0.05, compared with 
the 10:1 effector-target ratio, ○P<0.05.
4. Discussion
  The minimal residual disease in patients is still the main 
cause of leukemia relapse. Generally, residual leukaemie 
cell can only be eliminated by the own body antitumor 
immuno-protection mechanism when all of the leukemic 
cells less than 106[5]. As the key anti-tumor immune cells, 
DCs are important professional antigen-presenting cells. 
But usually the patients with leukemia have low immune 
function and that leading to tumor cells escape autoimmune. 
Therefore, this study observed the effect of co-culture CIK 
and homologous dendritic cells (DC) on the killing activity of 
leukemia HL-60[7-10].
  CIK cells come from T cell subsets. They are a group of 
heterogeneous cells isolated from peripheral blood, bone 
marrow or umbilical cord blood by multiple cytokines. It 
has multiple characteristics such as high tumor-cytotoxic 
effect and broad spectrum in killing of tumor cells. 
Current research focus on co-cultured CIK with DC. DC 
are the strongest antigen-presenting cells in vivo, also the 
only  antigen-presenting cells which can activate naive T 
lymphocyte[11-13]. Co-cultured CIK with DC can significantly 
stimulate the proliferation of naive T cells. This study 
suggests that cord blood CIK cells began proliferation at the 
first three days after culturing and quickly proliferated from 
the 5-6 days. At 12d of culturing cord blood CIK and DC 
cells, it is found that the proliferation of DC-CIK cells were 
significantly greater than the simple CIK cells.
  The CD3+ CD8+ cells percentage increased more 
significantly than a simple CIK and the IFN-C, TNF-
毩 and IL-8 which secreted by the CD3
+ CD8+ cells were 
significantly greater than the simple CIK cells. That not 
only enhanced the killing effect on leukemia cells, but also 
kill leukemic cells indirectly by regulating the immune 
system. The reason is because the number of DC-CIK cells 
proliferation increased significantly after stimulated by 
antigen, and because effector cells CIK whose efficient anti-
tumor activity is closely related to the double-positive cell 
levels of the CD3+ CD8+ cells and secrete cytokines such as 
IL-8, IFN-C and TNF-毩. That directly or indirectly lead to 
enhanced tumoricidal activity. CIK cells can release large 
amounts of toxic particles and inflammatory cytokines which 
induce tumor cell apoptosis. Co-cultured with DC amplified 
the cytotoxic activity of CIK cells and promoted the release 
of inflammatory cytokines and remain active for a long 
time. Because of the sub-feedback effect, it can inhibite T 
cell numbers and reduced secretion of IL-10 which has an 
immunosuppressive function[14-20].
  In vitro experiment demonstrated that cord blood can be 
used as a source of CIK and DC and can co-cultured DC-
CIK. It is found that the DC-CIK proliferated significantly, 
which can enhance its anti-leukemia effect. Cord blood 
have wide raw material sources thus easy to solve the 
problem of shortage of materials, which are also unlikely to 
cause immune rejection, so it is think that cord blood can be 
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widely used in the clinical application for the co-culture of 
DC-CIKs.
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